literature

HIV mutation literature information.

HIV Drug Resistance Mutations in Patients with HIV and HIV-TB Coinfection After Failure of First-Line Therapy: A Prevalence Study in a Resource-Limited Setting.

PMID: 31117863 2019 Journal of the International Association of Providers of AIDS Care

Table: Y188C

Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens.

PMID: 30863788 2019 Open forum infectious diseases

Method: Nucleoside reverse-transcriptase inhibitor DRMs included M41I/L, D67N/E, K70R, M184V, T215Y/F/C/S, K219Q/E; NNRTI DRM included K103N, Y181C, G190A/S/R, L100I, K101E, V106I/M, Y188H/C/L, M230I/L.

Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.

PMID: 30769200 2019 International journal of antimicrobial agents

Abstract: Intermediate DOR resistance was defined as detection of any of V106A/M, Y188C/H, V108I, and K103N+P225H.

Drug resistance evolution in patients with human immunodeficiency virus-1 under long-term antiretroviral treatment-failure in Yunnan Province, China.

PMID: 30621727 2019 Virology journal

Discussion: We observed that NNRTI mutations principally occurred in the first and second periods of treatment failure and were mainly K103 N/R/S, V179D/E, Y181C/I/V, G190A, Y188L/C.

Long-term virological outcome in children receiving first-line antiretroviral therapy.

PMID: 30477526 2018 AIDS research and therapy

Result: K103N (48%), Y181C (37%), G190A/S (25%), Y188C/L (10%), V106M/A (8%), K65R (8%) and L100I (4%) were the major NNRTI DRMs observed in these 52 children.

Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes.

PMID: 29239896 2018 AIDS (London, England)

Result: Among the NNRTI failure patients, two patients had K103N and V106M/Y188CH mutation respectively.

Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.

PMID: 29566538 2018 Antiviral chemistry & chemotherapy

Method: Plasma samples contained a median of 3 [Q1-Q3: 2-4] NNRTI-associated drug resistance mutations which included A98G, L100I, K101E/H, K103N/S, V106M, V108I, E138A/K, V179D/E Y181C, Y188L/C, G190A, H221Y, P225H, F227L, and M230L.

Detection of minority drug resistant mutations in Malawian HIV-1 subtype C-positive patients initiating and on first-line antiretroviral therapy.

PMID: 29977795 2018 African journal of laboratory medicine

Result: Other NNRTI mutations, such as V90I, K103N, V106A/M, E138A, V179E, Y181C, Y188C/L and G190E were also found in one or two samples.

Table: Y188C

Research on the treatment effects and drug resistances of long-term second-line antiretroviral therapy among HIV-infected patients from Henan Province in China.

PMID: 30442114 2018 BMC infectious diseases

Table: Y188C

Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.

PMID: 30409215 2018 AIDS research and therapy

Result: Most of these minority drug resistance mutations were detected in the 67 cART-experienced individuals, e.g., the HIV-1 genotype of the following patients consisted of a mixture of majority and minority drug resistance mutations: patient SG79 (PR V11I 99.9%, K20I 99.9%; RT E44D 1.3%, D67N 1.1%, L100I 1.7%, M184V 84.9%, M184I 14.8%, K219Q 2.1%, INT E157Q 99.8%), patient SG86 (RT M184V 99.8%, INT L74M 97.9%, L74I 1.9%, E92Q 86

Browser Board

Co-occurred Entities

Filtrator